{
  "kind": "treatment",
  "slug": "clopenthixol",
  "type": "antipsychotic",
  "name": "Clopenthixol",
  "summary": "A typical antipsychotic from the thioxanthene class, used in the treatment of schizophrenia and other psychoses.",
  "description": "Clopenthixol is a first-generation (typical) antipsychotic of the thioxanthene class. It is primarily used for managing schizophrenia and related psychotic disorders. Like other typical antipsychotics, it acts mainly as a dopamine D2 receptor antagonist. It may also have sedative properties and is available in both oral and long-acting injectable forms in some countries.",
  "category": "medications/antipsychotics",
  "tags": [
    "typical-antipsychotic",
    "schizophrenia",
    "psychosis"
  ],
  "metadata": {
    "drug_classes": [
      "Thioxanthene Antipsychotic"
    ],
    "therapeutic_categories": [
      "Psychosis",
      "Schizophrenia"
    ],
    "mechanism_categories": [
      "Dopamine Blocker"
    ],
    "administration_routes": [
      "Oral",
      "Injection"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Sordinol",
      "Etaperazine"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry"
    ],
    "fda_approval_year": 1961
  },
  "clinical_metadata": {
    "primary_indications": [
      "Psychosis"
    ],
    "off_label_uses": [
      "Mania",
      "Agitation in dementia"
    ],
    "contraindications": [
      "Coma",
      "CNS depression",
      "Bone marrow suppression",
      "Pheochromocytoma"
    ],
    "monitoring_required": [
      "Extrapyramidal symptoms",
      "Tardive dyskinesia",
      "Metabolic parameters"
    ],
    "efficacy_rating": {
      "schizophrenia": 3,
      "mania": 2
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "clopenthixol",
      "sordinol",
      "etaperazine",
      "typical antipsychotic"
    ],
    "synonyms": [
      "zuclopenthixol related compound",
      "clopenthixol hydrochloride"
    ],
    "common_misspellings": [
      "clopentixol",
      "clopenthixal"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Schizophrenia",
        "Other psychotic disorders",
        "Acute agitation (off-label, IM form)",
        "Mania (off-label)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Primarily antagonizes dopamine D2 receptors in the mesolimbic pathway, reducing positive symptoms of psychosis. Also has some antagonistic effects at histamine H1 and alpha-adrenergic receptors, contributing to sedation and hypotension."
    },
    {
      "type": "dosing",
      "adult": {
        "oral-start": "2–10 mg 1–3 times daily",
        "oral-maintenance": "20–30 mg/day in divided doses",
        "max": "Up to 100 mg/day depending on tolerance and indication"
      },
      "geriatric": "Start at lower doses due to increased sensitivity to side effects",
      "hepatic_impairment": "Use with caution; monitor closely",
      "renal_impairment": "Dose adjustment generally not required, but caution advised"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: Various strengths (country-dependent)",
        "Oral drops (in some markets)",
        "Intramuscular injection (short-acting, in some markets)"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Sedative effects may occur within hours; antipsychotic effects usually take several days to weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "sedation",
        "orthostatic hypotension",
        "dry mouth",
        "blurred vision",
        "constipation",
        "weight gain"
      ],
      "less_common": [
        "extrapyramidal symptoms",
        "hyperprolactinemia",
        "QT prolongation"
      ],
      "serious": [
        "tardive dyskinesia",
        "neuroleptic malignant syndrome",
        "agranulocytosis"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Increased mortality in elderly patients with dementia-related psychosis.",
      "other": [
        "Risk of extrapyramidal symptoms, especially at higher doses",
        "May prolong QT interval; use caution with other QT-prolonging drugs",
        "Avoid abrupt withdrawal to prevent symptom relapse"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "CNS depressants",
          "risk": "Additive sedation",
          "action": "Use with caution"
        },
        {
          "with": "Levodopa",
          "risk": "Reduced efficacy of levodopa",
          "action": "Avoid combination"
        },
        {
          "with": "QT-prolonging drugs",
          "risk": "Additive QT prolongation",
          "action": "Avoid or monitor ECG"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "EPS and tardive dyskinesia symptoms",
        "Metabolic parameters (weight, glucose, lipids)",
        "Blood pressure",
        "ECG in patients with cardiac risk factors"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if benefits outweigh risks; limited human data",
      "lactation": "Excreted in breast milk; avoid if possible",
      "pediatrics": "Not well studied; use not generally recommended",
      "geriatrics": "Increased sensitivity to sedation, hypotension, and EPS"
    },
    {
      "type": "tapering",
      "text": "Gradually taper over weeks to months to avoid relapse and withdrawal symptoms."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Less commonly used in the US, more prevalent in Europe",
        "Considered for patients not tolerating other typical antipsychotics",
        "Sedative properties can be useful for agitation but may impair functioning"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "WHO ATC/DDD Index",
          "url": "https://www.whocc.no/atc_ddd_index/"
        },
        {
          "label": "Maudsley Prescribing Guidelines",
          "url": "https://www.wiley.com/en-us/The+Maudsley+Prescribing+Guidelines+in+Psychiatry-p-9781119442608"
        }
      ]
    }
  ],
  "seo": {
    "title": "Clopenthixol: Typical Antipsychotic Overview",
    "description": "Comprehensive guide to clopenthixol, a typical antipsychotic for schizophrenia and psychotic disorders, including dosing, side effects, and monitoring."
  }
}
